Skip to main content
Equibles
INCY logo

INCY · Incyte Corp · Documents

Track INCY — free

Use INCY with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research INCY.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$120.97 -0.73 (-0.60%) At close · Nov 13 Play latest call Q3 2026 earnings call transcript
S&P 500 member Russell 1000 member Rebalance outlook locked
Market Cap
$24.66B
Shares
203.83M
Volume · Nov 13 950.75K Avg daily vol (3M) 1.61M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $5.14B up 21.2% 10-K filed Feb 10, 2026 Quarterly report FY2026 Q3 Revenue $1.56B up 14.0% 10-Q filed Oct 29, 2026 Latest results Financial results 8-K filed Oct 29, 2026 Earnings call Q3 2026 earnings call Held Oct 29, 2026
2026
Oct 29
Earnings call
Q3 2026 earnings call

Incyte Corp reported third-quarter revenue of $1.56 billion and net sales of $1.32 billion, both up 14%, and raised full-year total net sales guidance to $5,210 million to $5,300 million. Its pipeline includes six Phase III assets.

Oct 29
Quarterly report 10-Q FY2026 Q3, ended Sep 30
FDA approves JAKAFI XR extended release tablets

Incyte reported that the FDA approved JAKAFI XR extended release tablets in May 2026.

Revenue $1.56B ▲ 14.0% Net loss $784.8M Diluted EPS -$3.86
Read from the MD&A section
2 source passages
Incyte is a global biopharmaceutical company engaged in the discovery, development and commercialization of proprietary therapeutics. In May 2026, the FDA approved JAKAFI XR (ruxolitinib) extended release tablets Open the document at this passage
Oct 29
Current report 8-K
Financial results

Incyte reported third-quarter 2026 total revenue of $1.56 billion and total net sales of $1.32 billion, each increased 14%, and raised full-year 2026 total net sales guidance to $5,210 - $5,300 million.

Aug 31
Current report 8-K
Other events AI summary on its way
Jul 28
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $1.67B ▲ 37.7% Net income $585.61M ▲ 44.6% Diluted EPS $2.81 ▲ 37.7%
Jul 6
Current report 8-K
Other events AI summary on its way
Jun 22
Current report 8-K
Other events AI summary on its way
Jun 8
Current report 8-K
Other events AI summary on its way
Apr 28
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $1.27B ▲ 20.9% Net income $303.33M ▲ 91.7% Diluted EPS $1.47 ▲ 83.8%
Mar 6
Current report 8-K Events of Feb 27
Other events AI summary on its way
Feb 10
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $5.14B ▲ 21.2% Net income $1.29B ▲ 3845.0% Diluted EPS $6.41 ▲ 4173.3%
2025
Oct 28
Quarterly report 10-Q FY2025 Q3, ended Sep 30
Quarterly report for FY2025 Q3
Revenue $1.37B ▲ 20.0% Net income $424.17M ▲ 298.4% Diluted EPS $2.11 ▲ 290.7%
Apr 29
Quarterly report 10-Q FY2025 Q1, ended Mar 31
Quarterly report for FY2025 Q1
Revenue $1.05B ▲ 19.5% Net income $158.2M ▼ 6.7% Diluted EPS $0.80 ▲ 6.7%
Feb 10
Annual report 10-K FY2024, ended Dec 31
Annual report for FY2024
Revenue $4.24B ▲ 14.8% Net income $32.62M ▼ 94.5% Diluted EPS $0.15 ▼ 94.3%
Showing 1–50 of 154 documents
Key facts CIK 879169 CUSIP 45337C102 13F (30d) 725 filings 674 filers Visit website Investor relations